IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)Joanne Jones, Alasdair Coles, Jacqueline Shawcross et al.|Journal of Clinical Investigation|2009Cited by 299